Arrivo BioVentures Overview
- Founded
- 2015

- Status
- Private
- Employees
- 7

- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $49M

- Investors
- 3
Arrivo BioVentures General Information
Description
Developer of reformulated biopharmaceutical drugs designed to identify biologics and small molecules to improve patient care. The company's drugs are produced reformulated product or a new chemical entity, to identify regulatory strategies to expedite the path to approval through efficient clinical programs, enabling pharma/biotech companies to meet their drug demands to improve patient's lives.
Contact Information
- Aerial Center Executive Park
- 9001 Aerial Center Parkway, Suite 110
- Morrisville, NC 27560
- United States
Arrivo BioVentures Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Early Stage VC | 25-May-2016 | $49M | 0000 | Completed | Generating Revenue |
Arrivo BioVentures Executive Team (6)
Arrivo BioVentures Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArrivo BioVentures Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Azur Pharma | Corporation | Minority | 000 0000 | 000000 0 | |
Rex Health Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Solas BioVentures | Venture Capital | Minority | 000 0000 | 000000 0 |